ε-N-acetylaminocaproyl chloride | 43218-41-3

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: ε-N-acetylaminocaproyl chloride
• 英文别名: 6-acetylaminohexanoyl chloride；6-Acetamino-hexansaeurechlorid；6-Acetamidohexanoyl chloride
• CAS: 43218-41-3
• 化学式: C₈H₁₄ClNO₂
• 分子量: 191.658
• InChiKey: PEPAYMAZZOMWEY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  12
• 可旋转键数：
  6
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.75
• 拓扑面积：
  46.2
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  ε-N-acetylaminocaproyl chloride 、 3-苯丙酸甲酯 生成 methyl 3-[p-(ε-N-acetylaminocaproyl)phenyl]-propionate
  参考文献：
  名称：

  TAKEHSITA, TORU;XOGA, KEHNDZI;OTSU, AKIRA;NARITOMO, TATSUYUKI

  摘要：

  DOI：
• 作为产物：
  描述：

  醋氨己酸 在 氯化亚砜 作用下， 生成 ε-N-acetylaminocaproyl chloride
  参考文献：
  名称：

  炔丙醇中 β3-氨基酸衍生物的立体特异性合成：无需偶联剂的寡肽的高效溶液相合成

  摘要：

  β3-氨基酸的立体定向合成已经从容易获得的和对映体富集的炔丙醇开始。通过硒介导的碳-碳三键有机转化，这种转化只需三个步骤即可实现。这种方法特别有吸引力，因为反应性硒基羧酸硒苯基酯中间体可以被氨基酸衍生物的胺官能团捕获。通过这种策略，N 末端的链伸长已经受到影响。在不使用偶联剂的情况下，N-去保护和与其他硒-苯基硒代羧酸盐中间体的重复同源化产生了 β-和混合 α/β-寡肽。

  DOI：

  10.1002/chem.200900701

文献信息

• Aminocarboxylic acids, amino alcohols, or the derivatives thereof,
  申请人：Teijin Limited

  公开号：US04402975A1

  公开（公告）日：1983-09-06

  A compound represented by the following formula ##STR1## wherein R.sup.1 represents a hydrogen atom, an acyl group or an alkoxycarbonyl group; X.sup.1 represents an alkylene group having 3 to 6 carbon atoms, a 1,4-cyclohexylene group, or a 1,4-phenylene group, the alkylene group may be substituted by an alkyl group having 1 to 6 carbon atoms, and the 1,4-phenylene group may be substituted by 1 or 2 substituents selected from halogen atoms and alkoxy groups having 1 to 6 carbon atoms; R.sup.2 represents a hydrogen atom or a hydroxyl group and R.sup.3 represents hydrogen atom, or R.sup.2 and R.sup.3 together may form an oxo group (.dbd.O), and when X.sup.1 is other than the 1,4-phenylene group, R.sup.2 represents a hydrogen atom and R.sup.3 represents a bond between the carbon atoms to which R.sup.3 is bonded and that carbon atom of X.sup.1 which is adjacent to said carbon atom; X.sup.2 represents an alkylene group having 1 to 5 carbon atoms which may be substituted by an alkyl group having 1 to 6 carbon atoms or an amino group; and R.sup.4 represents the group --COOR.sup.5, --CH.sub.2 OR.sup.6 or --CONR.sup.7 R.sup.8 in which R.sup.5 represents a hydrogen atom or an alkyl group having 1 to 6 carbon atoms, R.sup.6 represents a hydrogen atom or an acyl group having 1 to 6 carbon atoms, and R.sup.7 and R are identical or different and represent a hydrogen atom or an alkyl group having 1 to 6 carbon atoms or taken together may form a 5- or 6-membered ring; or an acid addition salts of said compound wherein R.sup.1 represents a hydrogen atom or X.sup.2 represents an alkylene group having an amino group, or salts of said compound wherein R.sup.5 represents a hydrogen atom. The compounds represented by the above formula or their pharmaceutically acceptable salts are useful as anti-ulcer agents. The present invention also provides a process for producing the compounds or their pharmaceutically acceptable salts, which comprises acylating a protected derivative at the amino group of a corresponding acid halide with a corresponding substituted benzene in the presence of a Lewis acid; or reducing a corresponding compound in the presence of an inert solvent under conditions which induce reduction of the carbonyl group of said corresponding compound without substantially reducing the phenylene group of said corresponding compound; or dehydrating a corresponding compound.

  该化合物由以下公式表示##STR1## 其中R.sup.1代表氢原子、酰基或烷氧羰基；X.sup.1代表具有3至6个碳原子的烷基基团、1,4-环己基基团或1,4-苯基基团，该烷基基团可被具有1至6个碳原子的烷基基团取代，而1,4-苯基基团可被1或2个卤原子和具有1至6个碳原子的烷氧基团中选择的取代基所取代；R.sup.2代表氢原子或羟基，R.sup.3代表氢原子，或R.sup.2和R.sup.3一起可以形成氧羰基(.dbd.O)，当X.sup.1不是1,4-苯基基团时，R.sup.2代表氢原子，R.sup.3代表与R.sup.3结合的碳原子和X.sup.1中邻近所述碳原子之间的键；X.sup.2代表具有1至5个碳原子的烷基基团，该基团可被具有1至6个碳原子的烷基基团或氨基取代；R.sup.4代表基团--COOR.sup.5、--CH.sub.2 OR.sup.6或--CONR.sup.7 R.sup.8，其中R.sup.5代表氢原子或具有1至6个碳原子的烷基基团，R.sup.6代表氢原子或具有1至6个碳原子的酰基，而R.sup.7和R是相同或不同，代表氢原子或具有1至6个碳原子的烷基基团，或者一起形成一个5-或6-成员环；或者该化合物的酸盐，其中R.sup.1代表氢原子或X.sup.2代表具有氨基的烷基基团，或者该化合物的盐，其中R.sup.5代表氢原子。上述公式所表示的化合物或其药用盐作为抗溃疡剂是有用的。本发明还提供了一种制备该化合物或其药用盐的方法，包括在路易斯酸存在下，通过使相应酸卤衍生物在相应取代苯存在下酰化相应酸卤衍生物的氨基基团；或者在惰性溶剂存在下还原相应化合物，在诱导还原所述相应化合物的羰基但几乎不还原所述相应化合物的苯基团的条件下；或者脱水相应化合物。
• An activatable and tumor-targeting NIR fluorescent probe for imaging of histone deacetylase 6 in cancer cells and <i>in vivo</i>
  作者：Min Li、Jin Liu、Xuefei Chen、Yijing Dang、Yong Shao、Zhiai Xu、Wen Zhang

  DOI：10.1039/d1cc04640c

  日期：——

  An activatable and tumor-targeting near-infrared (NIR) fluorescent probe CyAc-RGD was synthesized for the imaging of histone deacetylase 6 (HDAC6). The probe exhibited higher sensitivity and specificity for HDAC6 detection in cancer cells. Moreover, CyAc-RGD demonstrated good tumor-targeting ability and realized HDAC6 imaging in vivo.

  合成了一种可激活且靶向肿瘤的近红外 (NIR) 荧光探针CyAc-RGD，用于组蛋白脱乙酰酶 6 (HDAC6) 的成像。该探针对癌细胞中的 HDAC6 检测表现出更高的灵敏度和特异性。此外，CyAc-RGD表现出良好的肿瘤靶向能力，实现了体内HDAC6成像。
• Pyridine compounds and pharmaceutical use thereof
  申请人：YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD.

  公开号：EP0359547A1

  公开（公告）日：1990-03-21

  A novel pyridine compound of the formula wherein R¹ and R² are the same or different and respectively mean hydrogen, a halogen, an alkyl, an alkoxy or an optionally substituted phenyl; Ar means an optionally substituted aryl or heteroaryl; Y means a single bond or an alkylene which may have double bond(s) in the chain; W means a group of the formula (wherein R³ and R⁴ are the same or different and respectively mean hydrogen, a halogen, an alkyl, an alkoxy or an optionally substituted phenyl, X means -O-, -S- or -N(R⁵)- (wherein R⁵ means hydrogen, an alkyl or an acyl), Z means a single bond, -O-, -S-, -N(R⁶)- (wherein R⁶ means hydrogen, an alkyl or an acyl) or -CON(R⁷)- (wherein R⁷ means hydrogen, an alkyl or an acyl), A means an alkylene, B means an alkoxycarbonyl, carboxyl, hydroxyl group, -N(R⁸)(R⁹) (wherein R⁸ and R⁹ are the same or different and respectively mean hydrogen, an alkyl, a hydroxyalkyl, an acyl or an optionally substituted aralkyl or heteroaralkyl or conbinedly means a group forming, taken together with the adjacent nitrogen, a heterocyclic group) or -CON(R¹⁰)(R¹¹) (wherein R¹⁰ and R¹¹ are the same or different and respectively mean hydrogen, an alkyl, a hydroxyalkyl, an acyl or an optionally substituted aralkyl or heteroaralkyl, or combinedly mean a group forming, taken together with the adjacent nitrogen, a heterocyclic group), a group of the formula (wherein R¹² and R¹³ are the same or different and respectively mean hydrogen, an alkyl, a hydroxyalkyl, an acyl, an optionally substituted phenyl or an optionally substituted aralkyl or heteroaralkyl, or combinedly mean a group forming, taken together with the adjacent nitrogen atom, a heterocyclic group, P means -O-, -S(O)p- (wherein p means an integer of 0 to 2), -N(R¹⁴)- (wherein R¹⁴ means hydrogen, an alkyl or an acyl) or -N(R¹⁵)CO- (wherein R¹⁵ means hydrogen, an alkyl or an acyl), Q means an alkylene having not less than 5 carbon atoms, a cyclic alkylene, an alkylene having not less than 4 carbon atoms which has an interposing oxygen or a sulfur therein or an alkylene having not less than 5 carbon atoms which has carbonyl group at the terminus, with the proviso that Q means an alkylene having not less than 3 carbon atoms, when P is -N(R¹⁵)CO-) or a group of the formula (wherein n means an integer of 3 to 5), or a salt thereof. The compounds exhibit inhibitory activity on prolylendopeptidase. Also disclosed are pharmaceutical compositions containing the novel pyridine compounds.

  一种新型吡啶化合物，其式如下 其中 R¹ 和 R² 相同或不同，分别表示氢、卤素、烷基、烷氧基或任选取代的苯基；Ar 表示任选取代的芳基或杂芳基；Y 表示单键或链中可能有双键的亚烷基；W 表示式中的基团 (其中 R³ 和 R⁴ 相同或不同，分别指氢、卤素、烷基、烷氧基或任选取代的苯基；X 指 -O-、-S- 或 -N(R⁵)-（其中 R⁵ 指氢、烷基或酰基）；Z 指单键、-O-、-S-、-N(R⁶)-（其中 R⁶ 指氢、烷基或酰基）或-CON(R⁷)-（其中 R⁷ 指氢、烷基或酰基），A 指亚烷基、B 表示烷氧基羰基、羧基、羟基、-N(R⁸)(R⁹)（其中 R⁸ 和 R𠞙 相同或不同，分别表示氢、烷基、羟基烷基或酰基）、烷基、羟基烷基、酰基或任选取代的芳烷基或杂烷基，或结合指与邻近的氮一起形成杂环基的基团）或 -CON(R¹⁰)(R¹¹)（其中 R¹⁰ 和 R¹¹ 相同或不同，分别表示氢、烷基、羟基烷基、酰基或任选取代的芳烷基或杂烷基，或与相邻的氮结合形成杂环基的基团），式中的基团 (其中 R¹² 和 R¹³ 相同或不同，分别指氢、烷基、羟基烷基、酰基、任选取代的苯基或任选取代的芳基或杂烷基，或合并指一个基团、P指-O-、-S(O)p-（其中 p 指 0 至 2 的整数）、-N(R¹⁴)-（其中 R¹⁴ 指氢、烷基或酰基）或-N(R¹⁵)CO-（其中 R¹⁵ 指氢、其中 R¹⁵ 指氢、烷基或酰基），Q 指具有不少于 5 个碳原子的亚烷基、环状亚烷基、具有不少于 4 个碳原子的亚烷基（其中有一个中间氧或一个硫）或具有不少于 5 个碳原子的亚烷基（其末端有羰基），但条件是当 P 为-N(R¹⁵)CO- 时，Q 指具有不少于 3 个碳原子的亚烷基）或式中的基团（其中 n 指整数）。 (其中 n 指 3 至 5 的整数）或其盐。 这些化合物对原内酯肽酶具有抑制活性。还公开了含有新型吡啶化合物的药物组合物。
• Pyridine compounds for treating amnesia
  申请人：YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD.

  公开号：EP0558094A1

  公开（公告）日：1993-09-01

  A novel compound of the formula wherein R¹ means hydrogen and R² means hydrogen or a straight-chain or branched chain alkyl having 1 to 8 carbon atoms; Ar means phenyl, a phenyl substituted by 1 to 3 substituent(s) selected from among halogens, straight-chain or branched chain alkyls having 1 to 8 carbon atoms, straight-chain or branched chain alkoxys having 1 to 8 carbon atoms, trifluoromethyl, amino, nitro and cyano, furyl, a furyl substituted by 1 to 3 substituent(s) selected from among halogens, straight-chain or branched chain alkyls having 1 to 8 carbon atoms, straight-chain or branched chain alkoxys having 1 to 8 carbon atoms, trifluoromethyl, straight-chain or branched chain alkylthiols having 1 to 8 carbon atoms, straight-chain or branched chain alkylsulfinyls having 1 to 8 carbon atoms, straight-chain or branched chain alkylsulfonyls having 1 to 8 carbon atoms, amino, nitro and cyano, thienyl, a thienyl substituted by 1 to 3 substituent(s) selected from among halogens, straight-chain or branched chain alkyls having 1 to 8 carbon atoms, straight-chain or branched chain alkoxys having 1 to 8 carbon atoms, trifluoromethyl, straight-chain or branched chain alkylthiols having 1 to 8 carbon atoms, straight-chain or branched chain alkylsulfinyls having 1 to 8 carbon atoms, straight-chain or branched chain alkylsulfonyls having 1 to 8 carbon atoms, amino, nitro and cyano, pyrrolyl, a pyrrolyl substituted by 1 to 3 substituent(s) selected from among halogens, straight-chain or branched chain alkyls having 1 to 8 carbon atoms, straight-chain or branched chain alkoxys having 1 to 8 carbon atoms, trifluoromethyl, straight-chain or branched chain alkylthiols having 1 to 8 carbon atoms, straight-chain or branched chain alkylsulfinyls having 1 to 8 carbon atoms, straight-chain or branched chain alkylsulfonyls having 1 to 8 carbon atoms, amino, nitro and cyano, pyridyl, or a pyridyl substituted by 1 to 3 substituent(s) selected from among halogens, straight-chain or branched chain alkyls having 1 to 8 carbon atoms, straight-chain or branched chain alkoxys having 1 to 8 carbon atoms, trifluoromethyl, straight-chain or branched chain alkylthiols having 1 to 8 carbon atoms, straight-chain or branched chain alkylsulfinyls having 1 to 8 carbon atoms, straight-chain or branched chain alkylsulfonyls having 1 to 8 carbon atoms, amino, nitro and cyano: Y means a single bond or a straight-chain or branched chain alkylene having 1 to 8 carbon atoms which may have double bond(s) in the chain; W means a group of the formula (i) (wherein R³ and R⁴ are the same or different and respectively mean hydrogen or a halogen, X means -O- or -S-, Z means a single bond or -O-, A is a straight-chain or branched chain alkylene having 1 to 8 carbon atoms, B means -N(R⁸)(R⁹) (wherein R⁸ and R⁹ are the same or different and respectively mean hydrogen or a straight-chain or branched chain alkyl having 1 to 8 carbon atoms, or combinedly means a group forming, taken together with the adjacent nitrogen, 1-pyrrolidinyl, 2-oxo-1-pyrrolidinyl, piperidino, 1-piperazinyl, a 1-piperazinyl substituted by a straight-chain or branched chain alkyl having 1 to 8 carbon atoms at the 4-position, 1-homopiperazinyl, morpholino and thiomorpholino) or a group of the formula (ii) (wherein R¹² and R¹³ are the same or different and respectively mean hydrogen or a straight-chain or branched chain alkyl having 1 to 8 carbon atoms, P is -S- and Q is hexamethylene, heptamethylene, octamethylene, 1-methylpentamethylene, 1-methylhexamethylene, 1-methylheptamethylene, -(CH₂)₂S(CH₂)₃-, -(CH₂)₂S(CH₂)₆-. or a pharmaceutically acceptable salt thereof or a hydrate thereof. The compounds exhibit inhibitory activity on prolylendopeptidase. Also disclosed are pharmaceutical compositions containing the novel pyridine compounds.

  一种新颖的式化合物 其中 R¹ 指氢，R² 指氢或具有 1 至 8 个碳原子的直链或支链烷基；Ar 指苯基、被 1 至 3 个取代基取代的苯基，这些取代基选自卤素、具有 1 至 8 个碳原子的直链或支链烷基、具有 1 至 8 个碳原子的直链或支链烷氧基、三氟甲基、氨基、硝基和氰基、呋喃基、被 1 至 3 个取代基取代的呋喃基，这些取代基选自卤素、具有 1 至 8 个碳原子的直链或支链烷基、具有 1 至 8 个碳原子的直链或支链烷氧基、三氟甲基、具有 1 至 8 个碳原子的直链或支链烷硫基、具有 1 至 8 个碳原子的直链或支链烷基亚磺酰基、具有 1 至 8 个碳原子的直链或支链烷基磺酰基、氨基、硝基和氰基、噻吩基、被 1 至 3 个从卤素中选出的取代基取代的噻吩基、具有 1 至 8 个碳原子的直链或支链烷基、具有 1 至 8 个碳原子的直链或支链烷氧基、三氟甲基、具有 1 至 8 个碳原子的直链或支链烷硫基、具有 1 至 8 个碳原子的直链或支链烷基亚磺酰基、具有 1 至 8 个碳原子的直链或支链烷基磺酰基、氨基、硝基和氰基、吡咯基、被 1 至 3 个选自卤素的取代基取代的吡咯基、具有 1 至 8 个碳原子的直链或支链烷基、具有 1 至 8 个碳原子的直链或支链烷氧基、三氟甲基、具有 1 至 8 个碳原子的直链或支链烷硫基、具有 1 至 8 个碳原子的直链或支链烷基亚磺酰基、具有 1 至 8 个碳原子的直链或支链烷基磺酰基、氨基、硝基和氰基、吡啶基或被 1 至 3 个取代基取代的吡啶基，取代基可从卤素、具有 1 至 8 个碳原子的直链或支链烷基、具有 1 至 8 个碳原子的直链或支链烷氧基中选出、三氟甲基、1 至 8 个碳原子的直链或支链烷硫基、1 至 8 个碳原子的直链或支链 烷基亚磺酰基、1 至 8 个碳原子的直链或支链烷基磺酰基、氨基、硝基和氰基：Y 指单键或具有 1 至 8 个碳原子的直链或支链亚烷基，链中可能有双键； W 指式(i)的基团 (其中 R³ 和 R⁴ 相同或不同，分别指氢或卤素，X 指 -O- 或 -S-，Z 指单键或 -O-，A 指具有 1 至 8 个碳原子的直链或支链亚烷基，B 指 -N(R⁸)(R⁹)（其中 R⁸ 和 R𠞙 相同或不同，分别指氢或具有 1 至 8 个碳原子的直链或支链烷基、或组合指与邻近的氮一起形成的基团、1-吡咯烷基、2-氧代-1-吡咯烷基、哌啶基、1-哌嗪基、在 4 位上被具有 1 至 8 个碳原子的直链或支链烷基取代的 1-哌嗪基、1-高哌嗪基、吗啉基和硫代吗啉基）或式 (ii) 的基团 (其中 R¹² 和 R¹³ 相同或不同，分别指氢或具有 1 至 8 个碳原子的直链或支链烷基、P 是-S-，Q 是六亚甲基、七亚甲基、八亚甲基、1-甲基五亚甲基、1-甲基六亚甲基、1-甲基七亚甲基、-(CH₂)₂S(CH₂)₃-、-(CH₂)₂S(CH₂)₆-。 或 其药学上可接受的盐或其水合物。 这些化合物对原内酯肽酶具有抑制活性。还公开了含有新型吡啶化合物的药物组合物。
• Aminocarboxylic acids, amino alcohols, or the derivatives thereof, processes for production thereof, and pharmaceutical composition, containing at least one of these compounds
  申请人：TEIJIN LIMITED

  公开号：EP0044541B1

  公开（公告）日：1983-09-21